Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1)
Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines
Julkaisun tekijät: Haveri Anu, Ikonen Niina, Savolainen-Kopra Carita, Julkunen Ilkka
Kustantaja: ELSEVIER SCI LTD
Julkaisuvuosi: 2021
Journal: Vaccine
Tietokannassa oleva lehden nimi: VACCINE
Lehden akronyymi: VACCINE
Volyymi: 39
Julkaisunumero: 2
Aloitussivu: 402
Lopetussivun numero: 411
Sivujen määrä: 10
ISSN: 0264-410X
eISSN: 1873-2518
DOI: http://dx.doi.org/10.1016/j.vaccine.2020.11.041
Verkko-osoite: https://www.sciencedirect.com/science/article/pii/S0264410X20314948?via=ihub
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/53037038
Background: Avian influenza A(H5N1) viruses have caused sporadic infections in humans and thus they pose a significant global health threat. Among symptomatic patients the case fatality rate has been ca. 50%. H5N1 viruses exist in multiple clades and subclades and several candidate vaccines have been developed to prevent A(H5N1) infection as a principal measure for preventing the disease.
Methods: Serum antibodies against various influenza A(H5N1) Glade viruses were measured in adults by ELISA-based microneutralization and haemagglutination inhibition tests before and after vaccination with two different A(H5N1) vaccines in 2009 and 2011.
Results: Two doses of AS03-adjuvanted A/Indonesia/5/2005 vaccine induced good homologous but poor heterologous neutralizing antibody responses against different Glade viruses. However, non-adjuvanted A/Vietnam/1203/2004 booster vaccination in 2011 induced very strong and long-lasting homologous and heterologous antibody responses while homologous response remained weak in naive subjects.
Conclusions: Sequential vaccination with two different A(H5N1) pre-pandemic vaccines induced long-lasting high level cross-Glade immunity against influenza A(H5N1) strains, thus supporting a prime-boost vaccination strategy in pandemic preparedness plans.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
